Targeting MyD88: Therapeutic mechanisms and potential applications of the specific inhibitor ST2825
ConclusionTargeting MyD88 is a novel therapeutic strategy, and scientific research is presently focused on the development of MyD88 inhibitors. The peptidomimetic compound ST2825 is a widely studied small-molecule inhibitor of MyD88. Thus, ST2825 may be a potential therapeutic small-molecule agent for modulating host immune regulation in inflammatory diseases and inflammatory therapy.
Source: Inflammation Research - Category: Research Source Type: research
More News: Autoimmune Disease | Brain | Databases & Libraries | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Lupus | Lymphoma | Neurology | Neuroscience | Research | Study | Transplants | Urology & Nephrology